

# VITAMIN D

## EVALUATING THE EVIDENCE

Robert P. Heaney, MD, FACP, FASN



*Creighton University Osteoporosis Research Center*

# MY FOCI

---

- early life
- measuring & assessing 25(OH)D
- other



# *Early Life*

## Deficiency – a working definition:

- a deficiency is any condition in which inadequate intake of a nutrient results in significant dysfunction or disease
- conversely, nutrient adequacy is the situation in which further increases in intake produce no further reduction in dysfunction or disease

# CLASSICAL VIT D DEFICIENCY

---

- rickets in children
- caused by poor absorption of calcium
  - › leading to high PTH levels,
  - › lowered renal phosphate threshold
  - › hypophosphatemia
- serum 25(OH)D: < 25 nmol/L
- clinically preventable by 200–400 IU D<sub>3</sub>/day
- that dose does *not* restore full Ca absorptive function *nor* normal bone histology

# RICKETS RISES AGAIN

---

- decreased sun exposure of babies
- maternal vitamin D deficiency
- failure to supplement infant feedings with vitamin D
- weaning infants to non-milk liquids

# **CRANIOTABES IN “NORMAL” INFANTS\***

**Note “hot cross bun” skull in this 5 mo old**

- 1120 consecutive neonates in Japan
- 22% had craniotabes
- median 25(OH)D at 1 mo: < 25 nmol/L


\*Yorifuji et al., JCEM; 93:1784-88 (2008)



# FETAL RICKETS\*

---

- $n = 424$
- 3D QUS
- splay index at distal femur at 19 & 34 weeks
- (metaphyseal X-sectional area divided by femoral length)
- high  $\approx$  rickets




\*Mahon et al., (2010) JBMR 25:14-19



# FETAL RICKETS\*

- n = 424
- 3D QUS
- splay index at distal femur




\*Mahon et al., (2010) JBMR 25:14-19

Maternal 25(OH)D (nmol/L)



*Battered child  
or  
unrecognized rickets?*

# UNDIAGNOSED METABOLIC BONE DISEASE



slide courtesy of Dr David Ayoub


# UNDIAGNOSED METABOLIC BONE DISEASE



slide courtesy of Dr David Ayoub

*Cases of apparent child abuse,  
particularly with little or no  
evidence of soft tissue injury, must  
be evaluated for metabolic bone  
disease before diagnosing abuse  
!*

Pre-Rx




Post-Rx



Patient of Dr. Lyndon Key, MUSC

*Her rickets have healed  
but –  
does she have subtle long-term  
consequences of early life vitamin  
D deficiency?*

# JUVENILE DIABETES IN FINLAND\*




\*Karvonen et al., (1999) Diabetes Care 22:1066-70



# JUVENILE DIABETES IN FINLAND\*

This dosage reflects the then common practice in E. Europe of giving 600,000 IU 3x per year during infancy




CU



ORC

# JUVENILE DIABETES IN FINLAND\*




CU



ORC

# NEONATAL VIT D & DIABETES\*


---

- 10,366 northern Finnish children
  - 2000 IU Vit D/d 1<sup>st</sup> year of life
  - prevalence of type I diabetes assessed at age 31
  - RR calculated vs. no supplementation
- 
- those who got the recommended amount regularly
  - those who got it sometimes
  - those who got it never
  - those who got little or no vit D at all & were thought to have rickets

\*Hypponen et al., Lancet 2001;358:1500-03

# NEONATAL VIT D & DIABETES\*


---

- 10,366 northern Finnish children
  - 2000 IU Vit D/d 1<sup>st</sup> year of life
  - prevalence of type I diabetes assessed at age 31
  - RR calculated vs. no supplementation
- 
- those who got the recommended amount regularly
  - those who got it sometimes
  - those who got it never
  - those who got little or no vit D at all & were thought to have rickets

\*Hypponen et al., Lancet 2001;358:1500-03

# NEONATAL VIT D & DIABETES\*

- 10,366 northern Finnish children
- 2000 IU Vit D/d 1<sup>st</sup> year of life
- prevalence of type I diabetes assessed at age 31
- RR calculated vs. no supplementation




\*Hypponen et al., Lancet 2001;358:1500-03


Vitamin D Administration

# NEONATAL VIT D & DIABETES\*

- EURODIAB Study
- 7 European cntrs
- case control 820 cases (~80 % eligible population)
- supplemental Vit D in infancy
- type 1 diabetes < age 15



# MS INCIDENCE MAP\*




*Percent national average incidence:*



\*modified from: <http://mscenter.ucsf.edu/>

# MS RISK & BIRTH MONTH\*


- 44,045 pts with MS
- populations of Canada, UK, Denmark, & Sweden
- observed cases divided by expected, by birth month






# MS RISK & BIRTH MONTH\*

- 44,045 pts with MS
- populations of Canada, UK, Denmark, & Sweden
- observed cases divided by expected, by birth month



# INFANT VITAMIN D INTAKE\*

- *Infant Feeding Practices Study*
- > 33,000 infants
- 2005-2007
- Sources (1 mo):
  - breast - 43%
  - formula - 26%
  - mixed - 32%



CU



ORC

\* Perrine et al. 2010, *Pediatrics* 125:627-32

These perinatal and early life associations are probably epigenetic in character and are believed to involve the programming of the immune system to distinguish self and non-self – a process in which vitamin D plays an essential role

# VIT D & PREGNANCY OUTCOMES\*

---

- DB-RCT; N = 690 pregnant women
- dosed with 400, 2000, & 4000 IU/d from wk 12 to delivery


CU



ORC


\*Hollis & Wagner (2009) in press

# VIT D & PREGNANCY OUTCOMES\*



\*Hollis & Wagner (2009) in press

# VIT D & PREGNANCY OUTCOMES\*



\*Wagner & Hollis (2010) in press

# VIT D & PREGNANCY OUTCOMES\*

---

- DB-RCT; N = 690 pregnant women
- dosed with 400, 2000, & 4000 IU/d from wk 12 to delivery
- **risk of untoward outcomes reduced by half:**
  - pre-term delivery (P < 0.01)
  - gestational diabetes, pre-eclampsia, hypertension (P < 0.01)
  - periodontal disease (P < 0.05)
  - neonatal infection (P < 0.05)

*Other*

*[Mechanisms]*




# CELL MODELS

---

*old:*

DNA in somatic cells functions mainly to make faithful copies for tissue repair or replacement



*new:*


DNA functions constantly in synthesis of needed cellular apparatus

# CELL MODELS

---

*old:*


cell/tissue differentiation meant that each cell type contained different cytoplasmic apparatus




*new:*

cell/tissue differentiation meant that only certain genes can be accessed in each tissue


# HOW A CELL RESPONDS




# HOW A CELL RESPONDS



# HOW A CELL RESPONDS




# VITAMIN D & INNATE IMMUNITY\*



# VITAMIN D & INNATE IMMUNITY\*


25(OH)D



# VITAMIN D & INNATE IMMUNITY\*

25(OH)D

- human monocytes in fetal calf serum






# VITAMIN D & INNATE IMMUNITY\*

## 25(OH)D


- human monocytes in fetal calf serum
- fetal calf serum is low in both 25(OH)D & 1,25(OH)<sub>2</sub>D



# VITAMIN D & INNATE IMMUNITY\*

25(OH)D


- human monocytes in fetal calf serum
- add  $1,25(\text{OH})_2\text{D}$  to the system



# VITAMIN D & INNATE IMMUNITY\*

## 25(OH)D

- human monocytes in fetal calf serum
- add 25(OH)D to the system




# VITAMIN D & TUBERCULOSIS

- human monocytes activated with *M. Tuberculosis* and incubated in human serum

- African-American
- White
- African-American with added 25(OH)D

## Cathelicidin mRNA




This scheme means that each tissue

- has the amount of  $1,25(\text{OH})_2\text{D}$  it needs
- when it needs it
- and is not dependent upon a "one-size-fits all" systemic level of circulating  $1,25(\text{OH})_2\text{D}$
- every time DNA is expressed, vitamin D is consumed

# VITAMIN D & TUBERCULOSIS\*

- 67 pts with pulmonary TB
- standard treatment for all
- in addition, randomized to either vit D 10,000 IU/d or placebo
- $P = 0.002$



Vitamin D *enables* macrophage  
function

It does not cause it

# INNATE IMMUNITY IN INFANTS

---

- infection resistance in infants heavily dependent upon innate immunity
- human monocytes cultured in cord blood plasma\*
  - macrophage expression of cathelicidin mRNA directly related to cord blood 25(OH)D
  - low 25(OH)D samples rescued by added 25(OH)D



# *Measurement & Assessment*

# CHRONIC DISEASE PERSPECTIVE

---

- chronic disease is the breakdown of structure and/or function of a body system
- its origin is usually multifactorial
  - genes
  - environment
    - ✓ nutrition
    - ✓ infection
    - ✓ toxins
    - ✓ injury

*the body has*

*vitamin D is an essential*

*low vitamin D status  
impairs this protective/  
reparative activity*

# THE PREVENTIVE MAINTENANCE MODEL

---

## *foundational premises:*

- all tissues need all nutrients
- shortages impair the functioning of *all* body systems
- premature organ/system “wearing out”, as a consequence of nutrient deficiency, will vary from person to person, depending on variable genetic composition

# THE PREVENTIVE MAINTENANCE MODEL

---


- *also recognizes that:*
  - the organism will work perfectly well without maintenance – *for a while . . .*
- it thus reconciles the seeming paradox that an organism can be “deficient” without being clinically “sick”
  - *for a while . . .*
- it’s also about squaring the morbidity/mortality curve

# VITAMIN D SHORTAGE


---

- when vitamin D is in short supply, the various tissues and cells of our bodies cannot make enough calcitriol to open up their DNA libraries adequately
- their functioning is thus impaired
- that, ultimately, is the basis for the multi-system manifestations of vit D deficiency


# A VITAMIN D THRESHOLD



# A VITAMIN D THRESHOLD



# A VITAMIN D THRESHOLD




CU



ORC



# A VITAMIN D THRESHOLD



CU



ORC

Vitamin D *enables* Ca absorption

It does not cause it

In general vitamin D *enables* tissue  
response & recovery

It does not cause it

# VIT D – CANONICAL SCHEME

---

skin

liver

kidney

gut

---



---

CU



ORC

---

# OLD VIT D - CANONICAL SCHEME

---

skin

liver

kidney

gut

---



---


CU




ORC

---


# VIT D – EXPANDED SCHEME



# VIT D – EXPANDED SCHEME



# VIT D – EXPANDED SCHEME






Won't calcitriol meet the  
body's need for vitamin D?

**NO!**

# VIT D – EXPANDED SCHEME




- Very recent studies have shown that, when serum 25(OH)D is normalized in patients on hemodialysis, serum 1,25(OH)<sub>2</sub>D is “normalized” as well.
- Bikle showed many years ago that the skin was able to synthesize physiologically meaningful quantities of 1,25(OH)<sub>2</sub>D.

How much is enough?


# THE RESPONSE THRESHOLD

---




# THE RESPONSE THRESHOLD

---




# THE RESPONSE THRESHOLD

---



# THE RESPONSE THRESHOLD

---






# THE RESPONSE THRESHOLD

---




# THE RESPONSE THRESHOLD

---



# THE RESPONSE THRESHOLD



# HOW MUCH IS ENOUGH?

---

- rickets & osteomalacia
  - clinical 25 nmol/L
  - histological 80 nmol/L
- Ca absorption 80 nmol/L
- fracture risk 100 nmol/L
- pregnancy outcomes 120 nmol/L
- cancer 100 nmol/L
- other ?????

# **STATUS OF THE EVIDENCE**

- **there are now more than 30 randomized controlled trials evaluating a causal connection between serum 25(OH)D levels and various health benefits**
  - **13+ osteoporotic fractures**
  - **5+ falls**
  - **2 hypertension**
  - **1 cancer**
  - **1 adjuvant tuberculosis therapy**
  - **3 respiratory infection/influenza risk**
  - **3 pregnancy outcomes**
  - **1 periodontal disease**
  - **3 insulin sensitivity & diabetes**

# STATUS OF THE EVIDENCE


- out of this total there are, to be sure, several null trials
- in general these failed trials either –
  - used too low a dose
  - had poor compliance
  - failed to achieve a therapeutic blood level of 25(OH)D
  - failed to optimize co-nutrition
- there is only one negative trial

# STATUS OF THE EVIDENCE

---

- there are, to be sure, several null trials as well
- in general these failed trials either –
  - used too low a dose
  - had poor compliance
  - failed to achieve a therapeutic blood level of 25(OH)D
  - failed to optimize co-nutrition
- there is only one negative trial


# ACHIEVED 25(OH)D & HIP FRACTURE\*



\*Redrawn from Bischoff-Ferrari et al. *JAMA*. 2005;293:2257-2264




# ACHIEVED DOSE & FRACTURE EFFICACY\*



\* Redrawn from Bischoff-Ferrari et al.  
(2009) Arch Int Med; 169:551-561

# 25(OH)D RESPONSE TO LARGE DOSES\*

- 100,000 IU D<sub>3</sub>, by mouth, once



CU




ORC

\*Ilahi, Armas, & Heaney


# VARIABILITY OF 25(OH)D RESPONSE\*

- $\Delta$  25(OH)D to  $C_{\max}$  ranged from +12 nmol/L to +76 nmol/L
- ~half of the variability due to body size



# VARIABILITY OF 25(OH)D RESPONSE\*

- Wt-adjusted  $\Delta$  25(OH)D to  $C_{max}$  ranged from +20 nmol/L to +66 nmol/L



CU



ORC

\*Ilahi, Armas, & Heaney

# SUMMARY

---

- for some endpoints (e.g., pregnancy, cancer) the data suggest that 80 nmol/L is not high enough
- there is huge variability in individual response
- the emphasis must be on the achieved serum level, not on the oral dose

# SUMMARY

---

- levels of 100 – 200 nmol/L are physiological
- given the manifest safety of such levels, we should strive to achieve at least 100 nmol/L in all our patients & clients
- whatever their primary condition, most will be vitamin D-deficient as well
- their recovery will be aided by treating that D deficiency

# SUMMARY

---

- levels of 100 – 200 nmol/L are physiological
- given the manifest safety of such levels, we should strive to achieve at least 100 nmol/L in all our patients & clients
- whatever their primary condition, most will be vitamin D-deficient as well
- their recovery will be aided by treating that D deficiency

Thank you . . .